胃癌类器官在基础研究与临床应用中的进展

doi:10.16352/j.issn.1001-6325.2024.09.1219

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (9): 1219-1222.doi: 10.16352/j.issn.1001-6325.2024.09.1219

• 特邀专题：类器官及其芯片 • 上一篇下一篇

胃癌类器官在基础研究与临床应用中的进展

刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟^*

中国医学科学院基础医学研究所北京协和医学院基础学院重大疾病共性机制研究全国重点实验室,北京 100005

收稿日期:2024-06-26 修回日期:2024-07-11 出版日期:2024-09-05 发布日期:2024-08-30
通讯作者: ^*songwei@ibms.pumc.edu.cn
基金资助:
中国医学科学院医学与健康科技创新工程(2021-I2M-1-066)

Progress of gastric cancer organoids in basic research and clinical application

LIU Baoqing, HUANG Rong, LU Yan, LI Kai, ZHANG Ning, LIU Changzheng, SONG Wei^*

State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC, Beijing 100005, China

Received:2024-06-26 Revised:2024-07-11 Online:2024-09-05 Published:2024-08-30
Contact: ^*songwei@ibms.pumc.edu.cn

摘要/Abstract

摘要： 胃癌在全球癌症发病率和死亡率中均位居第5,具有高度的侵袭性和异质性,但由于缺乏表征胃癌发生进展特性的研究模型,胃癌的研究和治疗比较局限。胃癌类器官是一种在体外培育而成的多细胞三维结构,能够模拟原发胃癌的结构和功能,在建立胃癌研究模型、模拟体内肿瘤微环境、药物高通量筛选、发现治疗新靶点、预测临床治疗反应、指导个体化治疗等方面拥有巨大的应用潜力与发展前景。本文对胃癌类器官在基础研究与临床应用中的进展进行综述,以期推动临床前基础研究的进展,为胃癌的临床治疗提供支持。

关键词: 胃癌, 临床治疗, 类器官, 肿瘤微环境

Abstract: Gastric cancer ranks fifth in global cancer mortality, which is highly aggressive and heterogeneous. However, the research and treatment of gastric cancer is hindered by short of research models that may characterize the developmental properties of gastric cancer. Gastric cancer organoid is a multicellular three-dimensional structure developed in vitro, which can mimic the structure and function of native gastric cancer. Gastric cancer organoids have great application potential and development prospects in establishing gastric cancer research models, mimicking the tumor microenvironment, high-throughput screening of drugs, discovering new therapeutic targets, predicting clinical therapeutic responses, and guiding individualized treatment. In this paper, the progress of gastric cancer organoids in basic research and clinical application is reviewed aiming for promoting the progress of preclinical research and supporting the clinical treatment of gastric cancer.

Key words: gastric cancer, clinical treatment, organoid, tumor microenvironment

中图分类号:

R735.2

刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.

LIU Baoqing, HUANG Rong, LU Yan, LI Kai, ZHANG Ning, LIU Changzheng, SONG Wei. Progress of gastric cancer organoids in basic research and clinical application[J]. Basic & Clinical Medicine, 2024, 44(9): 1219-1222.

参考文献 25

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024,74:229-263.
[2]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46: 221-231.
[3]	Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention[J]. Nat Rev Clin Oncol, 2023,20:338-349.
[4]	Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022,33:1005-1020.
[5]	Sato T, Vries R G, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche[J]. Nature, 2009,459:262-265.
[6]	LeSavage BL, Suhar RA, Broguiere N, et al. Next-generation cancer organoids[J]. Nat Mater, 2022,21:143-159.
[7]	Marx V. Closing in on cancer heterogeneity with organoids[J]. Nat Methods, 2024,21:551-554.
[8]	Yan H, Chan AS, Lai FP, et al. Organoid cultures for cancer modeling[J]. Cell Stem Cell, 2023,30:917-937.
[9]	McCracken KW, Catá EM, Crawford CM, et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids[J]. Nature, 2014,516:400-404.
[10]	Huang XZ, Pang MJ, Li JY, et al. Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis[J]. Nat Commun, 2023,14:822. doi: 10.1038/s41467-023-36310-9.
[11]	Koh V, Chakrabarti J, Torvund M, et al. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids[J]. Cancer Lett, 2021,518:59-71.
[12]	Yao L, Hou J, Wu X, et al. Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation[J]. Redox Biol, 2023,67:102923. doi:10.1016/j.redox.2023.102923.
[13]	Zhao H, Cheng Y, Kalra A, et al. Generation and multiomic profiling of a TP53/CDKN2A double-knoc-kout gastroesophageal junction organoid model[J]. Sci Transl Med, 2022,14:eabq6146. doi:10.1126/scitranslmed.abq6146.
[14]	Zhang F, Sahu V, Peng K, et al. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer[J]. Gut, 2024:gutjnl-2023-329686. doi: 10.1136/gutjnl-2023-329686.
[15]	Arai J, Hayakawa Y, Tateno H, et al. Impaired glycosylation of gastric mucins drives gastric tumorigenesis and serves as a novel therapeutic target[J]. Gastroenterology, 2024. doi:10.1053/j.gastro.2024.03.037.
[16]	Mircetic J, Camgöz A, Abohawya M, et al. CRISPR/Cas9 screen in gastric cancer patient-derived organoids reveals KDM1A-NDRG1 axis as a targetable vulnerability[J]. Small Methods, 2023,7:e2201605. doi:10.1002/smtd.202201605.
[17]	Peng K, Zhang F, Wang Y, et al. Development of combination strategies for focal adhesion kinase inhibition in diffuse gastric cancer[J]. Clin Cancer Res, 2023,29:197-208.
[18]	Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers[J]. Science, 2018,359:920-926.
[19]	Zu M, Hao X, Ning J, et al. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing[J]. Biomed Pharmacother, 2023,163:114751. doi:10.1016/j.biopha.2023.114751.
[20]	Schmäche T, Fohgrub J, Klimova A, et al. Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold[J]. Mol Cancer, 2024,23:10. doi:10.1186/s12943-023-01919-3.
[21]	Lin W, Zhang Y, Yang Y, et al. Anti-PD-1/Her2 bispecific antibody IBI315 enhances the treatment effect of Her2-positive gastric cancer through gasdermin B-cleavage induced pyroptosis[J]. Adv Sci (Weinh), 2023,10:e2303908. doi:10.1002/advs.202303908.
[22]	Kwon JW, Oh JS, Seok SH, et al. Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency[J]. Mol Cancer, 2023,22:156. doi:10.1186/s12943-023-01857-0.
[23]	Dao L, You Z, Lu L, et al. Modeling blood-brain barrier formation and cerebral cavernous malformations in human PSC-derived organoids[J]. Cell Stem Cell, 2024,31:818-833.
[24]	Hwangbo H, Chae S, Kim W, et al. Tumor-on-a-chip models combined with mini-tissues or organoids for engineering tumor tissues[J]. Theranostics, 2024,14:33-55.
[25]	Wu J, Li T, Guo M, et al. Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue[J]. Cell Discov, 2024,10:45. doi:10.1038/s41421-024-00662-3.

胃癌类器官在基础研究与临床应用中的进展

Progress of gastric cancer organoids in basic research and clinical application

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨振丽, 夏雨佳, 刘玉琴. 器官芯片——更具前景的体外模型[J]. 基础医学与临床, 2024, 44(9): 1202-1207.
[2]	夏雨佳, 杨振丽, 代娣, 刘玉琴. 乳腺癌类器官的培养及鉴定[J]. 基础医学与临床, 2024, 44(9): 1223-1228.
[3]	夏雨佳, 杨振丽, 刘玉琴. 肿瘤类器官临床前转化研究及应用[J]. 基础医学与临床, 2024, 44(9): 1214-1218.
[4]	王靓, 夏隆阔, 张建民. 脑类器官在药物研发中的研究进展[J]. 基础医学与临床, 2024, 44(9): 1208-1213.
[5]	侯楠, 刘源, 高俊, 王晶, 袁萌. 全血NPM1、MCP-1和肠道菌群与胃癌进展及预后相关[J]. 基础医学与临床, 2024, 44(8): 1137-1142.
[6]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[7]	朱宛宛, 周金娟, 修建波. 小分子化合物组合改善多能干细胞向脑类器官定向分化的效率[J]. 基础医学与临床, 2024, 44(6): 786-792.
[8]	李炜康, 李东宝, 任嘉裕, 孙小童, 段开鹏, 周进. Ghrelin在胃癌中的作用[J]. 基础医学与临床, 2024, 44(10): 1460-1464.
[9]	郑彬彬, 林淑莹, 李德隆, 陈杰, 黄子成. 环状RNA ATP2B1靶向miR-452-5p降低胃癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2023, 43(6): 882-888.
[10]	张海灵, 杨玉, 周倩倩, 汪远金, 王婷. 微囊藻毒素-LR处理的中性粒细胞NETs促进结直肠癌细胞迁移[J]. 基础医学与临床, 2023, 43(6): 967-973.
[11]	张智玉, 曹军, 梁俊波. 利用Hnf4α敲除的小鼠肝脏类器官探究发育模型的应用潜力[J]. 基础医学与临床, 2023, 43(5): 724-732.
[12]	卢琰, 周雅博, 陈洁. 利用类器官培养构建小鼠肝脏衰老模型[J]. 基础医学与临床, 2023, 43(4): 554-559.
[13]	谢晓婷, 张雷, 张莉, 董凤, 刘颖, 李光华, 杨兴. ASH2L在幽门螺旋杆菌感染的人胃癌细胞系中的表达及临床意义[J]. 基础医学与临床, 2023, 43(3): 367-373.
[14]	杨蛟洋, 舒格格, 李东宝, 周进. 信号通路在胃癌转移中作用的研究进展[J]. 基础医学与临床, 2023, 43(11): 1707-1712.
[15]	刘东, 李庆妍, 王自全, 王丙武, 王保庆. 胃癌患者外周血miR-34a甲基化的检测及临床意义[J]. 基础医学与临床, 2023, 43(10): 1572-1576.